PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8580054-0	1995	Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC).	Etoposide	75-84	angiotensin I converting enzyme	Homo sapiens	86-89	
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	angiotensin I converting enzyme	Homo sapiens	105-108	
9363869-4	1997	All patients received three cycles of doxorubicin, cyclophosphamide, and etoposide (ACE).	Etoposide	73-82	angiotensin I converting enzyme	Homo sapiens	84-87	
7536433-2	1995	This study was conducted to test the feasibility of reducing the interval between cycles of doxorubicin, cyclophosphamide, etoposide (ACE) chemotherapy to 2 weeks, thereby increasing dose intensity, by adding granulocyte colony-stimulating factor (G-CSF) to reduce the duration of neutropenia following a cycle.	Etoposide	123-132	angiotensin I converting enzyme	Homo sapiens	134-137	
3020702-5	1986	A three drug combination of doxorubicin (Adriamycin), cyclophosphamide, and etoposide (ACE) has been used at the University of Maryland Cancer Center (UMCC) for more than a decade in sequential studies.	Etoposide	76-85	angiotensin I converting enzyme	Homo sapiens	87-90	
6282482-0	1982	Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.	Etoposide	34-42	angiotensin I converting enzyme	Homo sapiens	44-47	
19567453-1	2009	BACKGROUND: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL).	Etoposide	89-98	angiotensin I converting enzyme	Homo sapiens	100-103